A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

Completed · Not applicable

Conditions studied: Age Related Macular Degeneration (AMD)

In brief

This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular Degeneration (AMD) to detect a potential change in disease status.

Key facts

Study ID

NCT01542866

Run by

Novartis Pharmaceuticals

People needed

160

Starts

2011-01-11

Expected to finish

2011-11-30

Last updated by the study team

2018-07-12

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with CNV secondary to AMD and not other causes in at least one eye identified by the investigator to be eligible for ranibizumab treatment
• Patients with a BCVA letter score in the study eye is 24 or better using an ETDRS chart measured at 4 meters distance

You may not qualify if…

• Patients with any concurrent ocular condition that may result in visual loss during the study
• Patients with past (within the prior 6 months) or current use of, or likely need for, systemic medications that are known to be toxic to the lens, retina, or optic nerve
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Beverly Hills, California, United States
• Novartis Investigative Site — Sacramento, California, United States
• Novartis Investigative Site — Torrance, California, United States
• Novartis Investigative Site — Fort Myers, Florida, United States
• Novartis Investigative Site — Largo, Florida, United States
• Novartis Investigative Site — Sarasota, Florida, United States
• Novartis Investigative Site — Springfield, Illinois, United States
• Novartis Investigative Site — Williamsburg, Michigan, United States
• Novartis Investigative Site — Lincoln, Nebraska, United States
• Novartis Investigative Site — Omaha, Nebraska, United States
• Novartis Investigative Site — Las Vegas, Nevada, United States
• Novartis Investigative Site — Toms River, New Jersey, United States
• Novartis Investigative Site — New York, New York, United States
• Novartis Investigative Site — Rochester, New York, United States
• Novartis Investigative Site — Slingerlands, New York, United States
• Novartis Investigative Site — Charlotte, North Carolina, United States
• Novartis Investigative Site — Cincinnati, Ohio, United States
• Novartis Investigative Site — Cleveland, Ohio, United States
• Novartis Investigative Site — West Mifflin, Pennsylvania, United States
• Novartis Investigative Site — Rapid City, South Dakota, United States
• Novartis Investigative Site — Kingsport, Tennessee, United States
• Novartis Investigative Site — Nashville, Tennessee, United States
• Novartis Investigative Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.